Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy
DUE: February 20, 2024 This RFA will solicit applications for a pivotal phase 3 clinical trial to determine the efficacy of FDA approved monoclonal antibody therapy compared to placebo in diverse “mixed dementia” populations with Read More